Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0C9DA
|
|||
| Drug Name |
Calaspargase pegol
|
|||
| Synonyms |
UNII-T9FVH03HMZ; T9FVH03HMZ; Calaspargase pegol [USAN:INN]; EZN-2285
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Acute lymphocytic leukaemia [ICD-11: 2B33.3; ICD-10: C91, C91.9] | Approved | [1] | |
| Acute lymphoblastic leukaemia [ICD-11: 2A85; ICD-10: C85.1, C88.7; ICD-9: 204] | Phase 3 | [2] | ||
| Company |
Servier
|
|||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Asparaginase (ASRGL1) | Target Info | Inhibitor | [1] |
| BioCyc | Asparagine degradation | |||
| Pathwhiz Pathway | Aspartate Metabolism | |||
| Ammonia Recycling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from Children's Oncology Group Study AALL07P4. J Clin Oncol. 2014 Dec 1;32(34):3874-82. | |||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034060) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.